Q-omics provides the consensus-scored KRT80 profile across patient tissues and cancer cell-line models. KRT80 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KRT80 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, KRT80 RNA expression shows 15,572 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where KRT80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT80 survival associations across molecular data types. KRT80 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT80 RNA expression–survival associations across cancer types. High KRT80 expression shows unfavorable associations in MESO, LGG, PAAD, BLCA and LUAD, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KRT80 RNA expression.
This table summarizes KRT80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KRT80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT80 shows higher tumor expression in COAD, LUAD, THCA, KIRP, READ and LUSC. The COAD box plot shows higher KRT80 RNA expression in tumor versus normal tissue (log2 FC = +5.298, t-test p < 0.001).
This table shows molecular features associated with KRT80 in patient tissues and cancer cell lines. In patient samples, KRT80 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT80 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
